HLA-A

Summary

HLA-A (major histocompatibility complex, class I, A, HGNC:4931) is a protein-coding gene on chromosome 6p22.1, encoding HLA class I histocompatibility antigen, A alpha chain (P04439). Antigen-presenting major histocompatibility complex class I (MHCI) molecule.

HLA-A belongs to the HLA class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy chain is anchored in the membrane. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen so that they can be recognized by cytotoxic T cells. They are expressed in nearly all cells. The heavy chain is approximately 45 kDa and its gene contains 8 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the alpha1 and alpha2 domains, which both bind the peptide, exon 4 encodes the alpha3 domain, exon 5 encodes the transmembrane region, and exons 6 and 7 encode the cytoplasmic tail. Polymorphisms within exon 2 and exon 3 are responsible for the peptide binding specificity of each class one molecule. Typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. More than 6000 HLA-A alleles have been described. The HLA system plays an important role in the occurrence and outcome of infectious diseases, including those caused by the malaria parasite, the human immunodeficiency virus (HIV), and the severe acute respiratory syndrome coronavirus (SARS-CoV). The structural spike and the nucleocapsid proteins of the novel coronavirus SARS-CoV-2, which causes coronavirus disease 2019 (COVID-19), are reported to contain multiple Class I epitopes with predicted HLA restrictions. Individual HLA genetic variation may help explain different immune responses to a virus across a population.

Source: NCBI Gene 3105 — RefSeq curated summary.

At a glance

• GWAS associations: 90
• Clinical variants (ClinVar): 91 total — 1 likely-pathogenic
• Phenotypes (HPO): 23
• Druggable target: yes — 8 molecules with ChEMBL bioactivity
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 14 cancer types
• MANE Select transcript: NM_002116

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4931
Approved symbol	HLA-A
Name	major histocompatibility complex, class I, A
Location	6p22.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000206503
Ensembl biotype	protein_coding
OMIM	142800
Entrez	3105

Gene structure

Transcript identifiers

Ensembl transcripts: 36 — 24 protein_coding, 9 retained_intron, 3 nonsense_mediated_decay

ENST00000376802, ENST00000376806, ENST00000376809, ENST00000396634, ENST00000461903, ENST00000479320, ENST00000495183, ENST00000496081, ENST00000638375, ENST00000706892, ENST00000706893, ENST00000706894, ENST00000706895, ENST00000706896, ENST00000706897, ENST00000706898, ENST00000706899, ENST00000706900, ENST00000706901, ENST00000706902, ENST00000706903, ENST00000706904, ENST00000706905, ENST00000714446, ENST00000897456, ENST00000897457, ENST00000897458, ENST00000934587, ENST00000934588, ENST00000934589, ENST00000934590, ENST00000934591, ENST00000952342, ENST00000952343, ENST00000952344, ENST00000952345

RefSeq mRNA: 1 — MANE Select: NM_002116 NM_002116

CCDS: CCDS34373

Canonical transcript exons

ENST00000376809 — 8 exons

Exon	Start	End
ENSE00003515521	29945234	29945281
ENSE00003518731	29944500	29944616
ENSE00003617747	29944122	29944397
ENSE00003618247	29945059	29945091
ENSE00003893776	29942757	29943026
ENSE00003895764	29943268	29943543
ENSE00003997344	29942532	29942626
ENSE00003997356	29945451	29945870

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 99.84.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 408.2201 / max 6605.7548, expressed in 1771 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
66677	402.6666	1771
66681	2.7465	937
66679	1.6202	739
203934	1.1868	817

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	99.84	gold quality
granulocyte	CL:0000094	99.81	gold quality
stromal cell of endometrium	CL:0002255	99.76	gold quality
spleen	UBERON:0002106	99.73	gold quality
mucosa of transverse colon	UBERON:0004991	99.73	gold quality
duodenum	UBERON:0002114	99.66	gold quality
right lung	UBERON:0002167	99.65	gold quality
upper lobe of left lung	UBERON:0008952	99.64	gold quality
vermiform appendix	UBERON:0001154	99.63	gold quality
lymph node	UBERON:0000029	99.62	gold quality
gall bladder	UBERON:0002110	99.60	gold quality
leukocyte	CL:0000738	99.59	gold quality
small intestine Peyer’s patch	UBERON:0003454	99.58	gold quality
monocyte	CL:0000576	99.56	gold quality
left adrenal gland	UBERON:0001234	99.54	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	99.53	gold quality
right adrenal gland	UBERON:0001233	99.51	gold quality
transverse colon	UBERON:0001157	99.50	gold quality
bone marrow	UBERON:0002371	99.49	gold quality
left lobe of thyroid gland	UBERON:0001120	99.47	gold quality
right adrenal gland cortex	UBERON:0035827	99.47	gold quality
left adrenal gland cortex	UBERON:0035825	99.46	gold quality
skin of abdomen	UBERON:0001416	99.45	gold quality
small intestine	UBERON:0002108	99.45	gold quality
zone of skin	UBERON:0000014	99.44	gold quality
cortex of kidney	UBERON:0001225	99.43	gold quality
skin of leg	UBERON:0001511	99.43	gold quality
right lobe of thyroid gland	UBERON:0001119	99.41	gold quality
subcutaneous adipose tissue	UBERON:0002190	99.41	gold quality
body of uterus	UBERON:0009853	99.41	gold quality

Single-cell (SCXA)

Detected in 30 experiment(s), a significant marker in 23.

Experiment	Marker?	Max mean expression
E-CURD-85	yes	5566.74
E-MTAB-6308	yes	4163.48
E-MTAB-8410	yes	2870.73
E-CURD-79	yes	2727.92
E-MTAB-6653	yes	2457.42
E-MTAB-6701	yes	1939.26
E-GEOD-134144	yes	1510.53
E-MTAB-5061	yes	1503.39
E-HCAD-8	yes	1460.72
E-MTAB-9467	yes	1435.20
E-MTAB-10553	yes	1359.37
E-GEOD-81547	yes	1206.24
E-MTAB-7051	yes	992.79
E-GEOD-76312	yes	365.47
E-GEOD-81608	yes	308.42

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CIITA, HIVEP2, IRF1, JUN, MYC, MYCN, NFKB1, NKX2-1, PAX8, REL, RELA, STAT1, TAF1, TP53, YY1, ZFX, ZNF91

miRNA regulators (miRDB)

63 targeting HLA-A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488
HSA-MIR-548W	99.94	71.24	3488
HSA-MIR-548Y	99.94	71.28	3514
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-1299	99.77	71.24	2389

Literature-anchored findings (GeneRIF, showing 35)

• magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype (PMID:11752149)
• Proposed association of A24 and A26 with schizophrenia in Japan was not confirmed. (PMID:11840504)
• Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8. HLA-A2, -Cw4, and -Bw46 alleles, or HLA-G1 leads to NK cell apoptosis. (PMID:11861287)
• Disparate binding of chaperone proteins by HLA-A subtypes (PMID:11862383)
• HLA-A*3303 restricts an HIV-1 Vpu epitope associated with non-progression. (PMID:11953475)
• Eight new HLA-A alleles associated with antigens in the A2 CREG. (PMID:12028541)
• two new HLA-A alleles, A*2419 and A* 3011, that were initially recognized by an aberrant serological pattern. (PMID:12028542)
• Polymorphisms in HIV-1 reverse transcriptase were most evident at sites of least functional or structural constraint and frequently were associated with particular host HLA-A and HLA-B alleles (PMID:12029127)
• a soluble recombinant HLA-A*1101 molecule has been expressed and used to assemble a complex with beta2-microglobulin and a Nef decapeptide. (PMID:12077441)
• The HLA class I A locus affects susceptibility to type 1 diabetes. (PMID:12121673)
• The nucleotide sequences of HLA-A*1112 exons 2 and 3 are identical to HLA-A*11011 except for a single nucleotide substitution in codon 90 (GAC–>GCC). (PMID:12366787)
• HLA-A*6818 N displays a sequence identical to that of the HLA-A*6802 allele. This duplication creates a shift of the reading frame, which leads to a premature non-sense codon at position 59 of the null allele. (PMID:12366788)
• The new allele HLA-B*4431 only displayed B44 seroreactivity, which demonstrates that epitopes crucial for B60(40) specificity must be located in the alpha1 domain. (PMID:12366789)
• The allelic product of HLA-B*3531 is composed of B35 in its alpha1 domain and of B61(40) in its alpha2 domain. Both specificities are only weakly detectable with available sera. (PMID:12366790)
• Nef binds directly to the HLA-A2 cytoplasmic tail (PMID:12414957)
• HLA-A allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. (PMID:12472660)
• results indicate that the most prominent effect of Nef on HLA-A2 in T cells was to inhibit transport to the cell surface (PMID:12584329)
• HLA-A, -B, and -DRB1 alleles in a total of 236 Taiwanese adults with Graves’ disease and 533 racially matched normal control subjects were examined (PMID:12694583)
• Familial predisposition to IgA nephropathy is associated with HLA antigens and particular candidate genes. (PMID:12768083)
• identified 21 critical polymorphic functional residue positions (CPFRP) that significantly reduced functional pocket variability to just 189 among 212 HLA-A alleles (PMID:12826374)
• A computational method was used to predict the serologic specificity of HLA molecules encoded by HLA-A. (PMID:12859593)
• A Gambian TNF haplotype matches the European HLA-A1, B8, DR3 and Chinese HLA-A33, B58, DR3 haplotypes. (PMID:12859597)
• a novel HLA-A0201-restricted cytotoxic T lymphocyte (CTL)-epitope (28-SLYKFSPFPL; FSP06) derived from a mutant O-linked N-acetylglucosamine transferase (PMID:14601650)
• we examine the contribution of the HLA region to the clinical phenotype of UC. (PMID:14617036)
• HLA alleles plays an important role in the development of central nervous system meningiomas. (PMID:14693734)
• The frequency of haplotypes HLA-A in systemic lupus erythematosus group was significantly higher than that of control. (PMID:14748996)
• HLA-A*2402 together with microsatellite D6S248-15 allele could be B27-independent markers of additional susceptibility gene/s localised in the region telomeric to HLA-A in Basque ankylosing spondylitis patients. (PMID:14969772)
• In patients with autoimmune thyroiditis the HLA-A24 frequency of was higher than control values while in patients with polyglandular activation of autoimmunity, the HLA-A3 frequency was found to be higher. (PMID:15046556)
• selective down-regulation of HLA-A and HLA-Bw6 allospecificities associated with HLA-Bw4 preservation in leukemic cells (PMID:15070694)
• Significant increase in frequency of HLA-A were observed in leprosy patients when compared with controls. (PMID:15072129)
• Novel conditions are required for priming and antigen-specific expansion of cytotoxic T cells reactive to the HIV-1 p17 Gag(77-85) epitope on circulating naive CD8+ precursor cells derived from HLA-A*0201 HIV-seronegative healthy donors. (PMID:15100263)
• The apparent association of HLA-A*1101 with resistance to HIV-1 infection may reflect, at least in part, an interplay of functional advantages that particular structural features of the peptide-binding groove may confer to HLA-A*1101. (PMID:15128805)
• Results indicate that mutations at both position 65 and position 66 influence peptide binding by the human class I major histocompatibility complex molecule HLA-A2 to various extents. (PMID:15131131)
• identification of a new variant of the A*2607 allele, named A*260702 (PMID:15191527)
• These results suggest that the HLA-A*3303-B*4403-DRB1*1302 haplotype plays an important role in the development of PHN after herpes zoster, but not in the onset of herpes zoster. (PMID:15275783)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:ch211-147g22.4	ENSDARG00000097275
danio_rerio	mhc1lia	ENSDARG00000097766
danio_rerio		ENSDARG00000115781

Paralogs (22): HFE (ENSG00000010704), FCGRT (ENSG00000104870), ULBP1 (ENSG00000111981), ULBP2 (ENSG00000131015), ULBP3 (ENSG00000131019), MR1 (ENSG00000153029), RAET1L (ENSG00000155918), CD1D (ENSG00000158473), CD1A (ENSG00000158477), CD1C (ENSG00000158481), CD1B (ENSG00000158485), CD1E (ENSG00000158488), AZGP1 (ENSG00000160862), RAET1E (ENSG00000164520), RAET1G (ENSG00000203722), MICB (ENSG00000204516), MICA (ENSG00000204520), HLA-C (ENSG00000204525), HLA-E (ENSG00000204592), HLA-G (ENSG00000204632), HLA-F (ENSG00000204642), HLA-B (ENSG00000234745)

Protein

Protein identifiers

HLA class I histocompatibility antigen, A alpha chain — P04439 (reviewed: P04439)

Alternative names: Human leukocyte antigen A

All UniProt accessions (10): P04439, A0A1W2PS24, A0A9L9PXF6, A0A9L9PXG1, A0A9L9PY26, A0A9L9PYF9, A0AAQ5BI30, B1PKY1, Q5SRN5, Q5SRN7

UniProt curated annotations — full annotation on UniProt →

Function. Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-A-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells. May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity. Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells. Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via IFNG-induced immunoproteasome or via endopeptidase IDE/insulin-degrading enzyme. Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9. Allele A01:01: Presents a restricted peptide repertoire including viral epitopes derived from IAV NP/nucleoprotein (CTELKLSDY), IAV PB1/polymerase basic protein 1 (VSDGGPNLY), HAdV-11 capsid L3/hexon protein (LTDLGQNLLY), SARS-CoV-2 3a/ORF3a (FTSDYYQLY) as well as tumor peptide antigens including MAGE1 (EADPTGHSY), MAGEA3 (EVDPIGHLY) and WT1 (TSEKRPFMCAY), all having in common a canonical motif with a negatively charged Asp or Glu residue at position 3 and a Tyr anchor residue at the C-terminus. A number of HLA-A01:01-restricted peptides carry a post-translational modification with oxidation and N-terminal acetylation being the most frequent. Fails to present highly immunogenic peptides from the EBV latent antigens. Allele A02:01: A major allele in human populations, presents immunodominant viral epitopes derived from IAV M/matrix protein 1 (GILGFVFTL), HIV-1 env (TLTSCNTSV), HIV-1 gag-pol (ILKEPVHGV), HTLV-1 Tax (LLFGYPVYV), HBV C/core antigen (FLPSDFFPS), HCMV UL83/pp65 (NLVPMVATV) as well as tumor peptide antigens including MAGEA4 (GVYDGREHTV), WT1 (RMFPNAPYL) and CTAG1A/NY-ESO-1 (SLLMWITQC), all having in common hydrophobic amino acids at position 2 and at the C-terminal anchors. Allele A03:01: Presents viral epitopes derived from IAV NP (ILRGSVAHK), HIV-1 nef (QVPLRPMTYK), HIV-1 gag-pol (AIFQSSMTK), SARS-CoV-2 N/nucleoprotein (KTFPPTEPK) as well as tumor peptide antigens including PMEL (LIYRRRLMK), NODAL (HAYIQSLLK), TRP-2 (RMYNMVPFF), all having in common hydrophobic amino acids at position 2 and Lys or Arg anchor residues at the C-terminus. May also display spliced peptides resulting from the ligation of two separate proteasomal cleavage products that are not contiguous in the parental protein. Allele A11:01: Presents several immunodominant epitopes derived from HIV-1 gag-pol and HHV-4 EBNA4, containing the peptide motif with Val, Ile, Thr, Leu, Tyr or Phe at position 2 and Lys anchor residue at the C-terminus. Important in the control of HIV-1, EBV and HBV infections. Presents an immunodominant epitope derived from SARS-CoV-2 N/nucleoprotein (KTFPPTEPK). Allele A23:01: Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response. Allele A24:02: Presents viral epitopes derived from HIV-1 nef (RYPLTFGWCF), EBV lytic- and latent-cycle antigens BRLF1 (TYPVLEEMF), BMLF1 (DYNFVKQLF) and LMP2 (IYVLVMLVL), SARS-CoV nucleocapsid/N (QFKDNVILL), as well as tumor peptide antigens including PRAME (LYVDSLFFL), all sharing a common signature motif, namely an aromatic residue Tyr or Phe at position 2 and a nonhydrophobic anchor residue Phe, Leu or Iso at the C-terminus. Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response. Allele A26:01: Presents several epitopes derived from HIV-1 gag-pol (EVIPMFSAL, ETKLGKAGY) and env (LVSDGGPNLY), carrying as anchor residues preferentially Glu at position 1, Val or Thr at position 2 and Tyr at the C-terminus. Allele A29:02: Presents peptides having a common motif, namely a Glu residue at position 2 and Tyr or Leu anchor residues at the C-terminus. Allele A32:01: Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response. Allele A68:01: Presents viral epitopes derived from IAV NP (KTGGPIYKR) and HIV-1 tat (ITKGLGISYGR), having a common signature motif namely, Val or Thr at position 2 and positively charged residues Arg or Lys at the C-terminal anchor. Allele A74:01: Presents immunodominant HIV-1 epitopes derived from gag-pol (GQMVHQAISPR, QIYPGIKVR) and rev (RQIHSISER), carrying an aliphatic residue at position 2 and Arg anchor residue at the C-terminus. May contribute to viral load control in chronic HIV-1 infection.

Subunit / interactions. Heterotrimer that consists of an alpha chain HLA-A, a beta chain B2M and a peptide (peptide-HLA-A-B2M). Early in biogenesis, HLA-A-B2M dimer interacts with the components of the peptide-loading complex composed of TAPBP, TAP1-TAP2, TAPBPL, PDIA3/ERP57 and CALR. Interacts with TAP1-TAP2 transporter via TAPBP; this interaction is obligatory for the loading of peptide epitopes delivered to the ER by TAP1-TAP2 transporter. Interacts with TAPBPL; TAPBPL binds peptide-free HLA-A-B2M complexes or those loaded with low affinity peptides, likely facilitating peptide exchange for higher affinity peptides. Only optimally assembled peptide-HLA-B2M trimer translocates to the surface of antigen-presenting cells, where it interacts with TCR and CD8 coreceptor on the surface of T cells. HLA-A (via polymorphic alpha-1 and alpha-2 domains) interacts with antigen-specific TCR (via CDR3 domains). One HLA-A molecule (mainly via nonpolymorphic alpha-3 domain) interacts with one CD8A homodimer (via CDR-like loop); this interaction ensures peptide-HLA-A-B2M recognition by CD8-positive T cells only. Alleles A23:01; A24:02 and A*32:01 interact (via Bw4 motif) with KIR3DL1 on NK cells; this interaction is direct. (Microbial infection) Interacts with HHV-8 MIR1 protein. (Microbial infection) Interacts with HTLV-1 accessory protein p12I.

Subcellular location. Cell membrane. Endoplasmic reticulum membrane.

Tissue specificity. Ubiquitous.

Post-translational modifications. (Microbial infection) Polyubiquitinated in a post ER compartment by interaction with human herpesvirus 8 MIR1 protein. This targets the protein for rapid degradation via the ubiquitin system. N-linked glycosylation at Asn-110.

Disease relevance. Alleles A02:01 and A24:02 are associated with increased susceptibility to diabetes mellitus, insulin-dependent (IDDM). In a glucose-dependent way, allele A02:01 may aberrantly present the signal peptide of preproinsulin (ALWGPDPAAA) on the surface of pancreatic beta cells to autoreactive CD8-positive T cells, potentially driving T-cell mediated cytotoxicity in pancreatic islets. Allele A24:02 may present the signal peptide of preproinsulin (LWMRLLPLL) and contribute to acute pancreatic beta-cell destruction and early onset of IDDM. Allele A03:01 is associated with increased susceptibility to multiple sclerosis (MS), an autoimmune disease of the central nervous system. May contribute to the initiation phase of the disease by presenting myelin PLP1 self-peptide (KLIETYFSK) to autoreactive CD8-positive T cells capable of initiating the first autoimmune attacks. Allele A26:01 is associated with increased susceptibility to Behcet disease (BD) in the Northeast Asian population. Especially in the HLA-B51-negative BD populations, HLA-A26 is significantly associated with the onset of BD. Allele A*29:02 is associated with increased susceptibility to birdshot chorioretinopathy (BSCR). May aberrantly present retinal autoantigens and induce autoimmune uveitis.

Domain organisation. The alpha-1 domain is a structural part of the peptide-binding cleft. The alpha-2 domain is a structural part of the peptide-binding cleft. Mediates the interaction with TAP1-TAP2 complex. The alpha-3 Ig-like domain mediates the interaction with CD8 coreceptor. The VL9 peptide/epitope (VMAPRT[V/L][L/V/I/F]L) derived from the signal sequence is loaded onto HLA-E and enables HLA-E expression at the plasma membrane. Distinct VL9 peptides presented by HLA-E variably affect its recognition by KLRD1-KLRC1 or KLRD1-KLRC2 receptors on NK cells, setting NK cell activation threshold. Common HLA-A allotypes contain functional VL9 peptides (VMAPRTLLL, VMAPRTLVL and VPAPRTLLL).

Induction. Up-regulated by IFNG, and pro-inflammatory cytokines IL1B and TNF.

Polymorphism. Highly polymorphic. Polymorphic residues encode for alpha-1 and alpha-2 domains of the peptide-binding cleft, where they contribute to variations in peptide binding and TCR recognition among different alleles. The human population is estimated to have millions of HLA-A alleles. But only 11 common HLA-A alleles are considered core alleles, representing all functionally significant variation (polymorphism) in alpha-1 and alpha-2 domains. These are: A01:01; A02:01; A02:05; A03:01; A11:01; A24:02; A26:01; A29:02; A30:01; A74:01 and A80:01. Among these, A02:01; A11:01; A24:02 and A26:01, were likely passed by introgression from archaic to modern humans. Functional alleles of more recent origin (non-core) were derived by recombination. The sequence shown is that of A03:01. The sequences of core alleles and common representative alleles of serologically distinct allele groups are described as variants of A03:01. Allelic variations of HLA-A signal peptide regulate HLA-E recognition by KLRD1-KLRC1 and KLRD1-KLRC2 receptors in viral infection and tumorigenesis by affecting its processing and by changing the affinity of HLA-E-VL9 complex for KLRD1-KLRC1 and KLRD1-KLRC2 receptors. Allele A31:01 is associated with carbamazepine-induced hypersensitivity reactions among subjects of Northern European ancestry [MIM:608579].

Similarity. Belongs to the MHC class I family.

Isoforms (2)

UniProt ID	Names	Canonical?
P04439-1	1	yes
P04439-2	2

RefSeq proteins (1): NP_002107* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001039	MHC_I_a_a1/a2	Domain
IPR003006	Ig/MHC_CS	Conserved_site
IPR003597	Ig_C1-set	Domain
IPR007110	Ig-like_dom	Domain
IPR010579	MHC_I_a_C	Domain
IPR011161	MHC_I-like_Ag-recog	Domain
IPR011162	MHC_I/II-like_Ag-recog	Homologous_superfamily
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR037055	MHC_I-like_Ag-recog_sf	Homologous_superfamily
IPR050208	MHC_class-I_related	Family

Pfam: PF00129, PF06623, PF07654

UniProt features (162 total): sequence variant 93, strand 23, binding site 9, helix 8, modified residue 8, region of interest 6, mutagenesis site 3, topological domain 2, disulfide bond 2, splice variant 2, signal peptide 1, chain 1, compositionally biased region 1, transmembrane region 1, glycosylation site 1, domain 1

Structure

Experimental structures (PDB)

403 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
3MRE	X-RAY DIFFRACTION	1.1
3D25	X-RAY DIFFRACTION	1.3
3MRG	X-RAY DIFFRACTION	1.3
6JOZ	X-RAY DIFFRACTION	1.35
5C0G	X-RAY DIFFRACTION	1.37
5N1Y	X-RAY DIFFRACTION	1.39
1I4F	X-RAY DIFFRACTION	1.4
1OGA	X-RAY DIFFRACTION	1.4
3MRB	X-RAY DIFFRACTION	1.4
3MRK	X-RAY DIFFRACTION	1.4
6J2A	X-RAY DIFFRACTION	1.4
1X7Q	X-RAY DIFFRACTION	1.45
5C0F	X-RAY DIFFRACTION	1.46
4U6Y	X-RAY DIFFRACTION	1.47
5C0E	X-RAY DIFFRACTION	1.49
5DDH	X-RAY DIFFRACTION	1.5
6Q3K	X-RAY DIFFRACTION	1.5
6J1W	X-RAY DIFFRACTION	1.5
5C0I	X-RAY DIFFRACTION	1.53
5EU5	X-RAY DIFFRACTION	1.54
2GTW	X-RAY DIFFRACTION	1.55
5NMH	X-RAY DIFFRACTION	1.55
2HN7	X-RAY DIFFRACTION	1.6
2V2W	X-RAY DIFFRACTION	1.6
2V2X	X-RAY DIFFRACTION	1.6
2VLL	X-RAY DIFFRACTION	1.6
3BGM	X-RAY DIFFRACTION	1.6
3GSO	X-RAY DIFFRACTION	1.6
3MRR	X-RAY DIFFRACTION	1.6
3PWN	X-RAY DIFFRACTION	1.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P04439-F1	88.15	0.77

Antibody-complex structures (SAbDab): 9 — 1W72, 3GJF, 3HAE, 4WUU, 6ID4, 7STF, 8UDR, 8VR9, 8VRA

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (9): 31; 97; 108; 140; 167; 170; 183; 183; 195

Post-translational modifications (8): 83, 343, 344, 349, 350, 352, 356, 359

Disulfide bonds (2): 125–188, 227–283

Glycosylation sites (1): 110

Mutagenesis-validated functional residues (3):

Position	Phenotype
110	impairs the recruitment of hla-a*02 in the peptide-loading complex.
156	impairs the maturation of a peptide-receptive hla-a*02-b2m complex.
158	impairs binding to tap1-tap2 transporter, resulting in impaired presentation of intracellular peptides.

Function

Pathways and Gene Ontology

Reactome pathways

9 pathways

ID	Pathway
R-HSA-1236974	ER-Phagosome pathway
R-HSA-1236977	Endosomal/Vacuolar pathway
R-HSA-164940	Nef mediated downregulation of MHC class I complex cell surface expression
R-HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-877300	Interferon gamma signaling
R-HSA-8866654	E3 ubiquitin ligases ubiquitinate target proteins
R-HSA-909733	Interferon alpha/beta signaling
R-HSA-9705671	SARS-CoV-2 activates/modulates innate and adaptive immune responses
R-HSA-983170	Antigen Presentation: Folding, assembly and peptide loading of class I MHC

MSigDB gene sets: 505 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_POSITIVE_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, BENPORATH_ES_WITH_H3K27ME3, CHIBA_RESPONSE_TO_TSA_UP, GOBP_ANTIMICROBIAL_HUMORAL_RESPONSE, GOBP_REGULATION_OF_ALPHA_BETA_T_CELL_ACTIVATION, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_OF_CLASS_I_MHC, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, MODULE_151, GOBP_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, ENK_UV_RESPONSE_KERATINOCYTE_UP, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION_INVOLVED_IN_IMMUNE_RESPONSE

GO Biological Process (26): T cell mediated cytotoxicity (GO:0001913), positive regulation of T cell mediated cytotoxicity (GO:0001916), T cell mediated cytotoxicity directed against tumor cell target (GO:0002419), antigen processing and presentation of endogenous peptide antigen via MHC class Ib (GO:0002476), antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-dependent (GO:0002485), antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent (GO:0002486), peptide antigen assembly with MHC class I protein complex (GO:0002502), positive regulation of T cell cytokine production (GO:0002726), immune response (GO:0006955), detection of bacterium (GO:0016045), antibacterial humoral response (GO:0019731), antigen processing and presentation of endogenous peptide antigen via MHC class I (GO:0019885), positive regulation of type II interferon production (GO:0032729), CD8-positive, alpha-beta T cell activation (GO:0036037), protection from natural killer cell mediated cytotoxicity (GO:0042270), antigen processing and presentation of exogenous peptide antigen via MHC class I (GO:0042590), innate immune response (GO:0045087), defense response to Gram-positive bacterium (GO:0050830), T cell receptor signaling pathway (GO:0050852), positive regulation of CD8-positive, alpha-beta T cell proliferation (GO:2000566), positive regulation of memory T cell activation (GO:2000568), positive regulation of CD8-positive, alpha-beta T cell activation (GO:2001187), adaptive immune response (GO:0002250), immune system process (GO:0002376), antigen processing and presentation of peptide antigen via MHC class I (GO:0002474), antigen processing and presentation (GO:0019882)

GO Molecular Function (9): RNA binding (GO:0003723), signaling receptor binding (GO:0005102), beta-2-microglobulin binding (GO:0030881), peptide antigen binding (GO:0042605), T cell receptor binding (GO:0042608), CD8 receptor binding (GO:0042610), TAP binding (GO:0046977), TAP complex binding (GO:0062061), protein binding (GO:0005515)

GO Cellular Component (19): Golgi membrane (GO:0000139), obsolete extracellular space (GO:0005615), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), Golgi apparatus (GO:0005794), Golgi medial cisterna (GO:0005797), plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), cell surface (GO:0009986), ER to Golgi transport vesicle membrane (GO:0012507), membrane (GO:0016020), phagocytic vesicle membrane (GO:0030670), early endosome membrane (GO:0031901), MHC class I protein complex (GO:0042612), MHC class I peptide loading complex (GO:0042824), recycling endosome membrane (GO:0055038), extracellular exosome (GO:0070062), endoplasmic reticulum exit site (GO:0070971), lumenal side of endoplasmic reticulum membrane (GO:0098553)

Reactome top-level categories

Rollup of top-7 pathways:

Category	Pathways
Antigen processing-Cross presentation	2
Interferon Signaling	2
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters	1
Adaptive Immune System	1
Protein ubiquitination	1
SARS-CoV-2-host interactions	1
Class I MHC mediated antigen processing & presentation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
antigen processing and presentation of peptide antigen via MHC class I	3
protein binding	3
cellular anatomical structure	3
T cell mediated cytotoxicity	2
positive regulation of T cell mediated immunity	2
antigen processing and presentation of endogenous peptide antigen	2
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway	2
defense response to bacterium	2
signaling receptor binding	2
protein-containing complex binding	2
cytoplasm	2
endomembrane system	2
intracellular membrane-bounded organelle	2
endosome membrane	2
endoplasmic reticulum membrane	2
leukocyte mediated cytotoxicity	1
T cell mediated immunity	1
positive regulation of leukocyte mediated cytotoxicity	1
regulation of T cell mediated cytotoxicity	1
T cell mediated immune response to tumor cell	1
antigen processing and presentation of peptide antigen via MHC class Ib	1
MHC class I protein complex assembly	1
peptide antigen assembly with MHC protein complex	1
T cell cytokine production	1
positive regulation of cytokine production involved in immune response	1
regulation of T cell cytokine production	1
immune system process	1
response to stimulus	1
response to bacterium	1
detection of other organism	1
antimicrobial humoral response	1
positive regulation of cytokine production	1
type II interferon production	1
regulation of type II interferon production	1
alpha-beta T cell activation	1
negative regulation of natural killer cell mediated cytotoxicity	1
antigen processing and presentation of exogenous peptide antigen	1
immune response	1
defense response to symbiont	1
antigen receptor-mediated signaling pathway	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

252 interactions, top by confidence:

A	B	Type	Score
B2M	HLA-A	psi-mi:“MI:0915”(physical association)	0.850
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
HLA-C	HLA-A	psi-mi:“MI:0914”(association)	0.670
CRIPTO	AIP	psi-mi:“MI:0914”(association)	0.640
CANX	PGRMC1	psi-mi:“MI:0914”(association)	0.570
B2M	TAPBP	psi-mi:“MI:0915”(physical association)	0.570
ERBB3	AIFM1	psi-mi:“MI:0914”(association)	0.570
HLA-A	STAT3	psi-mi:“MI:0915”(physical association)	0.550
ILK	HAX1	psi-mi:“MI:0914”(association)	0.530
MME	TMEM223	psi-mi:“MI:0914”(association)	0.530
SLC39A5	TMEM223	psi-mi:“MI:0914”(association)	0.530
TMEM30B	KLRG2	psi-mi:“MI:0914”(association)	0.530
IL13RA2	METTL15	psi-mi:“MI:0914”(association)	0.530
GABRE	FZD6	psi-mi:“MI:0914”(association)	0.530
LRRC4C	DVL2	psi-mi:“MI:0914”(association)	0.530
FCGRT	GOLIM4	psi-mi:“MI:0914”(association)	0.530
CD1B	TOR1B	psi-mi:“MI:0914”(association)	0.530
ERBB3	SLC31A1	psi-mi:“MI:0914”(association)	0.530
IL20RB	B4GALT5	psi-mi:“MI:0914”(association)	0.530
ZACN	GPAA1	psi-mi:“MI:0914”(association)	0.530

BioGRID (436): HLA-A (Two-hybrid), HLA-A (Affinity Capture-MS), HLA-A (Affinity Capture-MS), HLA-A (Affinity Capture-MS), HLA-A (Affinity Capture-MS), HLA-A (Affinity Capture-MS), HLA-A (Affinity Capture-Western), HLA-A (Affinity Capture-Western), HLA-A (Affinity Capture-MS), HLA-A (Affinity Capture-MS), HLA-A (Affinity Capture-MS), HLA-A (Affinity Capture-MS), HLA-A (Affinity Capture-MS), HLA-A (Affinity Capture-MS), HLA-A (Affinity Capture-MS)

ESM2 similar proteins: P01889, P01893, P01894, P01897, P01899, P01900, P01901, P01902, P03991, P04223, P04439, P06140, P10321, P13747, P13748, P13749, P13750, P13751, P13752, P13753, P14426, P14427, P16209, P16210, P16211, P16212, P16215, P16391, P17693, P18466, P30375, P30376, P30377, P30378, P30379, P30380, P30381, P30382, P30383, P30385

Diamond homologs: C1ITJ8, O19477, O35799, P01888, P01889, P01893, P01894, P01895, P01896, P01897, P01898, P01899, P01900, P01901, P01902, P03991, P04223, P04439, P06126, P06140, P06339, P10321, P13747, P13748, P13749, P13750, P13751, P13752, P13753, P13765, P14426, P14427, P14428, P14429, P14430, P14431, P14432, P15464, P15978, P15979

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
CIITA	“up-regulates quantity by expression”	HLA-A	“transcriptional regulation”
MYC	“down-regulates quantity by repression”	HLA-A	“transcriptional regulation”
SRC	unknown	HLA-A	phosphorylation
PRKCA	unknown	HLA-A	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 219 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Antigen Presentation: Folding, assembly and peptide loading of class I MHC	8	19.8×	2e-06
DAP12 interactions	6	18.0×	5e-05
CD209 (DC-SIGN) signaling	5	16.3×	4e-04
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	5	16.3×	4e-04
Downstream signal transduction	6	14.4×	2e-04
DAP12 signaling	6	13.9×	2e-04
RAF activation	6	12.7×	3e-04
Signaling by FGFR1 in disease	6	11.1×	5e-04

GO biological processes:

GO term	Partners	Fold	FDR
peptide antigen assembly with MHC class II protein complex	5	27.4×	2e-04
positive regulation of T cell mediated cytotoxicity	9	23.9×	1e-07
peptidyl-tyrosine phosphorylation	7	15.4×	8e-05
antigen processing and presentation of exogenous peptide antigen via MHC class II	5	14.2×	3e-03
positive regulation of immune response	5	12.5×	4e-03
positive regulation of T cell activation	5	11.6×	5e-03
cell surface receptor protein tyrosine kinase signaling pathway	12	10.9×	8e-07
semaphorin-plexin signaling pathway	5	10.4×	8e-03

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 14 cancer types — ACYC, AML, BL, BLCA, CEAD, CESC, COAD, DLBCLNOS, ESCA, HNSC, LUSC, MEL…(+2 more).

Clinical variants and AI predictions

ClinVar

91 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	6
Likely benign	5
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3256931	NM_002116.8(HLA-A):c.704_722del (p.Ala235fs)	Likely pathogenic

SpliceAI

1457 predictions. Top by Δscore:

Variant	Effect	Δscore
6:29943521:G:GT	donor_gain	1.0000
6:29943521:G:T	donor_gain	1.0000
6:29944603:G:GT	donor_gain	1.0000
6:29944606:G:GT	donor_gain	1.0000
6:29942623:GCGG:G	donor_gain	0.9900
6:29942788:C:CA	acceptor_gain	0.9900
6:29942795:C:CA	acceptor_gain	0.9900
6:29943022:GGCCG:G	donor_gain	0.9900
6:29943023:GCCG:G	donor_gain	0.9900
6:29943023:GCCGG:G	donor_gain	0.9900
6:29943027:G:GG	donor_gain	0.9900
6:29943522:A:T	donor_gain	0.9900
6:29944631:AAGG:A	donor_gain	0.9900
6:29945233:GGCA:G	acceptor_gain	0.9900
6:29945449:A:AG	acceptor_gain	0.9900
6:29945450:G:GG	acceptor_gain	0.9900
6:29942393:A:AG	acceptor_gain	0.9800
6:29942394:A:G	acceptor_gain	0.9800
6:29942399:C:CA	acceptor_gain	0.9800
6:29942399:C:G	acceptor_gain	0.9800
6:29942402:AG:A	acceptor_gain	0.9800
6:29942403:GG:G	acceptor_gain	0.9800
6:29942622:GGCGG:G	donor_gain	0.9800
6:29942623:GCGGG:G	donor_gain	0.9800
6:29942625:GG:G	donor_gain	0.9800
6:29942625:GGGTG:G	donor_loss	0.9800
6:29942626:GG:G	donor_gain	0.9800
6:29942626:GGTG:G	donor_loss	0.9800
6:29942627:GT:G	donor_loss	0.9800
6:29942628:TGAG:T	donor_loss	0.9800

AlphaMissense

2363 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:29944196:T:C	F232L	0.985
6:29944198:C:A	F232L	0.985
6:29944198:C:G	F232L	0.985
6:29942861:T:C	F60L	0.973
6:29942863:C:A	F60L	0.973
6:29942863:C:G	F60L	0.973
6:29944295:T:C	F265L	0.971
6:29944297:C:A	F265L	0.971
6:29944297:C:G	F265L	0.971
6:29943393:T:A	W157R	0.954
6:29943393:T:C	W157R	0.954
6:29944306:G:C	W268C	0.943
6:29944306:G:T	W268C	0.943
6:29944181:T:A	C227S	0.942
6:29944182:G:C	C227S	0.942
6:29943395:G:C	W157C	0.941
6:29943395:G:T	W157C	0.941
6:29944223:T:A	W241R	0.939
6:29944223:T:C	W241R	0.939
6:29942852:T:C	F57L	0.937
6:29942854:C:A	F57L	0.937
6:29942854:C:G	F57L	0.937
6:29944181:T:C	C227R	0.935
6:29944225:G:C	W241C	0.935
6:29944225:G:T	W241C	0.935
6:29942906:T:A	W75R	0.934
6:29942906:T:C	W75R	0.934
6:29944349:T:C	C283R	0.933
6:29944349:T:A	C283S	0.932
6:29944350:G:C	C283S	0.932

dbSNP variants (sampled 300 via entrez): RS1002052713 (6:29943787 C>G), RS1002713700 (6:29940650 G>A), RS1007638622 (6:29941768 C>T), RS1011336633 (6:29941075 T>A,C), RS1011367317 (6:29941479 T>C), RS1012575389 (6:29940571 C>G), RS1016509971 (6:29942309 C>T), RS1017671266 (6:29941834 T>C), RS1022324010 (6:29940702 G>A,T), RS1022353737 (6:29941079 C>T), RS1025114973 (6:29945979 C>G), RS1026282728 (6:29942287 C>T), RS1027191688 (6:29945913 G>A), RS1031566869 (6:29940998 A>G), RS1035850851 (6:29942353 G>A,T)

Disease associations

OMIM: gene MIM:142800 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (2): Stevens-Johnson syndrome (Orphanet:36426), Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum (Orphanet:95455)

HPO phenotypes

23 total (23 of 23 shown, HPO-id order):

HPO	Term
HP:0000518	Cataract
HP:0000532	Abnormal chorioretinal morphology
HP:0000541	Retinal detachment
HP:0000543	Optic disc pallor
HP:0000572	Visual loss
HP:0000610	Abnormal choroid morphology
HP:0000613	Photophobia
HP:0000622	Blurred vision
HP:0007843	Attenuation of retinal blood vessels
HP:0007906	Ocular hypertension
HP:0008046	Abnormal retinal vascular morphology
HP:0011505	Cystoid macular edema
HP:0011506	Choroidal neovascularization
HP:0011508	Macular hole
HP:0011531	Vitritis
HP:0030329	Retinal thinning on OCT
HP:0030530	Arcuate scotoma
HP:0030609	Photoreceptor layer loss on macular OCT
HP:0030644	Blind-spot enlargement
HP:0100014	Epiretinal membrane
HP:0100533	Inflammatory abnormality of the eye
HP:0100832	Vitreous floaters
HP:0200056	Macular scar

GWAS associations

90 associations (top):

Study	Trait	p-value
GCST000460_1	Nasopharyngeal carcinoma	4.000000e-20
GCST000549_24	HIV-1 control	2.000000e-08
GCST000662_4	Vitiligo	9.000000e-23
GCST000687_1	Nasopharyngeal carcinoma	5.000000e-67
GCST000912_1	Adverse response to carbamazepine	1.000000e-16
GCST001036_1	Drug-induced liver injury (amoxicillin-clavulanate)	2.000000e-10
GCST001316_5	IgE levels	1.000000e-15
GCST001364_5	IgA nephropathy	2.000000e-11
GCST001438_6	Crohn’s disease	2.000000e-10
GCST001679_5	Complement C3 and C4 levels	3.000000e-48
GCST001863_12	Beta-2 microglubulin plasma levels	2.000000e-22
GCST001863_13	Beta-2 microglubulin plasma levels	9.000000e-10
GCST001863_2	Beta-2 microglubulin plasma levels	1.000000e-08
GCST001863_3	Beta-2 microglubulin plasma levels	2.000000e-06
GCST002541_20	Menarche (age at onset)	3.000000e-10
GCST002837_1	Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide)	5.000000e-09
GCST003183_16	Setpoint viral load in HIV-1 infection	7.000000e-08
GCST003251_20	Late-onset myasthenia gravis	1.000000e-11
GCST003252_28	Systemic lupus erythematosus	6.000000e-06
GCST004521_12	Autism spectrum disorder or schizophrenia	2.000000e-12
GCST004521_171	Autism spectrum disorder or schizophrenia	4.000000e-14
GCST004521_177	Autism spectrum disorder or schizophrenia	3.000000e-12
GCST004521_216	Autism spectrum disorder or schizophrenia	5.000000e-13
GCST004521_218	Autism spectrum disorder or schizophrenia	5.000000e-11
GCST004521_247	Autism spectrum disorder or schizophrenia	4.000000e-09
GCST004521_263	Autism spectrum disorder or schizophrenia	7.000000e-17
GCST004521_268	Autism spectrum disorder or schizophrenia	7.000000e-12
GCST004521_295	Autism spectrum disorder or schizophrenia	6.000000e-18
GCST004521_44	Autism spectrum disorder or schizophrenia	2.000000e-17
GCST004521_51	Autism spectrum disorder or schizophrenia	9.000000e-14

EFO canonical traits (33, from GWAS)

EFO ID	Trait name
EFO:0000180	HIV-1 infection
EFO:0004984	complement C4 measurement
EFO:0005197	beta-2 microglobulin measurement
EFO:0004703	age at menarche
EFO:0006956	intraocular pressure change measurement
EFO:0004305	erythrocyte count
EFO:0004348	hematocrit
EFO:0007985	platelet crit
EFO:0007986	reticulocyte count
EFO:0004509	hemoglobin measurement
EFO:0008400	susceptibility to chickenpox measurement
EFO:0008402	susceptibility to cold sores measurement
EFO:0008401	susceptibility to shingles measurement
EFO:0008404	susceptibility to mumps measurement
EFO:0008406	susceptibility to plantar warts measurement
EFO:0007904	susceptibility to childhood ear infection measurement
EFO:1001253	maculopapular eruption
EFO:0005187	C-peptide measurement
EFO:0006941	grip strength measurement
EFO:0009270	heel bone mineral density
EFO:0008328	chronotype measurement
EFO:0009855	frontal fibrosing alopecia
EFO:1002004	drug hypersensitivity syndrome
EFO:0004615	apolipoprotein B measurement
EFO:0009819	comparative body size at age 10, self-reported
EFO:0004918	age at diagnosis
EFO:0007789	BMI-adjusted waist circumference
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0004842	eosinophil count
EFO:0007991	eosinophil percentage of leukocytes

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2632 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

8 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 88,661 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1116	RALOXIFENE HYDROCHLORIDE	4	28,574
CHEMBL1200561	DOXAZOSIN MESYLATE	4	11,917
CHEMBL1200798	TRAZODONE HYDROCHLORIDE	4	8,178
CHEMBL296419	ASTEMIZOLE	4	21,577
CHEMBL101253	VATALANIB	3	11,319
CHEMBL263429	DISOMOTIDE	2	12
CHEMBL263441	OVEMOTIDE	2	935
CHEMBL267930	SPIPERONE	2	6,149

PharmGKB: 1 entry (VIP=true, CPIC=true)

PharmGKB clinical annotations

14 annotations.

Variant	Type	Level	Drugs	Phenotypes
HLA-A*02:01	Toxicity	3	allopurinol	Severe Cutaneous Adverse Reactions
HLA-A*02:01	Toxicity	4	carbamazepine	Drug Hypersensitivity;Drug Reaction with Eosinophilia and Systemic Symptoms;Maculopapular Exanthema;Severe Cutaneous Adverse Reactions;Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis
HLA-A*02:07	Toxicity	3	zonisamide	Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis
HLA-A*02:07	Toxicity	3	lamotrigine	Maculopapular Exanthema;Severe Cutaneous Adverse Reactions;Stevens-Johnson Syndrome
HLA-A*11:01	Toxicity	3	levetiracetam	adverse events;Epilepsy
HLA-A*11:01	Toxicity	3	carbamazepine	Severe Cutaneous Adverse Reactions;Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis
HLA-A*24:02	Toxicity	3	phenytoin	Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis
HLA-A*24:02	Toxicity	3	dapsone	Drug Hypersensitivity
HLA-A*24:02	Toxicity	3	carbamazepine	Drug Reaction with Eosinophilia and Systemic Symptoms;Severe Cutaneous Adverse Reactions;Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis
HLA-A*31:01	Toxicity	1A	carbamazepine	Drug Hypersensitivity;Drug Reaction with Eosinophilia and Systemic Symptoms;Maculopapular Exanthema;Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis
HLA-A*31:01	Toxicity	3	oxcarbazepine	Drug Reaction with Eosinophilia and Systemic Symptoms
HLA-A*32:01	Toxicity	3	vancomycin	Drug Reaction with Eosinophilia and Systemic Symptoms
HLA-A*33:03	Toxicity	2B	allopurinol	Drug Hypersensitivity;Stevens-Johnson Syndrome
HLA-A*33:03	Toxicity	3	lamotrigine	Maculopapular Exanthema

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs1061235	HLA-A		0.00	0

PharmGKB dosing guidelines

5 guidelines.

Source	Drug	Guideline	Dosing?	Recommendation?
CPIC	carbamazepine	Annotation of CPIC Guideline for carbamazepine and HLA-A, HLA-B		yes
DPWG	carbamazepine	Annotation of DPWG Guideline for carbamazepine and HLA-A		yes
CPNDS	carbamazepine	Annotation of CPNDS Guideline for carbamazepine and HLA-A, HLA-B		yes
RNPGx	carbamazepine;oxcarbazepine	Annotation of RNPGx Guideline for carbamazepine, oxcarbazepine and HLA-A, HLA-B		yes
RNPGx	tebentafusp	Annotation of RNPGx Guideline for tebentafusp and HLA-A		yes

ChEMBL bioactivities

157 potent at pChembl≥5 of 161 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.77	IC50	1.698	nM	CHEMBL402482
8.70	IC50	2	nM	CHEMBL412034
8.66	IC50	2.198	nM	CHEMBL410648
8.64	IC50	2.301	nM	CHEMBL415611
8.49	IC50	3.199	nM	CHEMBL386178
8.49	IC50	3.199	nM	CHEMBL386299
8.48	IC50	3.304	nM	CHEMBL426344
8.40	IC50	3.999	nM	CHEMBL402481
8.37	IC50	4.295	nM	CHEMBL122183
8.35	IC50	4.498	nM	CHEMBL110989
8.31	IC50	4.898	nM	CHEMBL440266
8.24	IC50	5.794	nM	CHEMBL428098
8.24	IC50	5.794	nM	CHEMBL325914
8.15	IC50	7.096	nM	CHEMBL407614
8.12	IC50	7.499	nM	CHEMBL437514
8.12	IC50	7.499	nM	CHEMBL405270
8.10	IC50	7.998	nM	CHEMBL263228
8.05	IC50	8.892	nM	CHEMBL407429
8.05	IC50	8.954	nM	CHEMBL216627
8.05	IC50	8.851	nM	CHEMBL430065
8.03	IC50	9.29	nM	CHEMBL120035
8.00	IC50	10	nM	ALMPLYACI
7.96	IC50	11.09	nM	CHEMBL385441
7.94	IC50	11.51	nM	CHEMBL263173
7.94	IC50	11.51	nM	CHEMBL263685
7.93	IC50	11.69	nM	CHEMBL121646
7.92	IC50	11.99	nM	CHEMBL414923
7.92	IC50	11.99	nM	CHEMBL406562
7.89	IC50	13	nM	CHEMBL405580
7.84	IC50	14.29	nM	CHEMBL411527
7.84	IC50	14.29	nM	CHEMBL118138
7.82	IC50	15	nM	CHEMBL214423
7.82	IC50	15.21	nM	CHEMBL334056
7.80	IC50	16	nM	CHEMBL385884
7.77	IC50	16.9	nM	CHEMBL429894
7.77	IC50	16.98	nM	CHEMBL439360
7.76	IC50	17.22	nM	CHEMBL265220
7.72	IC50	19.1	nM	DISOMOTIDE
7.70	IC50	20	nM	CHEMBL263600
7.70	IC50	20	nM	CHEMBL437069
7.68	IC50	20.8	nM	CHEMBL263599
7.66	IC50	21.98	nM	CHEMBL431673
7.64	IC50	22.8	nM	CHEMBL331323
7.64	IC50	22.7	nM	CHEMBL266418
7.58	IC50	26	nM	CHEMBL217741
7.58	IC50	26	nM	CHEMBL214420
7.58	IC50	26	nM	CHEMBL323837
7.55	IC50	27.99	nM	CHEMBL118999
7.53	IC50	29.38	nM	CHEMBL415514
7.48	IC50	33.04	nM	CHEMBL437069

PubChem BioAssay actives

157 with measured affinity, of 163 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0017	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0020	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0022	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0023	uM
(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]propanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0032	uM
(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]propanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0032	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0033	uM
(2S)-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0040	uM
(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]propanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0043	uM
(2S)-2-[[2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0045	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0049	uM
(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]propanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0058	uM
(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0058	uM
(2S,3S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0071	uM
(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0075	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0075	uM
(2S)-2-[[(2S,3S)-2-[[2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0080	uM
(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0089	uM
(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0089	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0090	uM
(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]propanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0093	uM
(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylpentanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0100	uM
(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0111	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0115	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0115	uM
(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0117	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0120	uM
(4S)-4-[[(2S)-6-amino-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-5-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(1S)-1-carboxy-2-methylpropyl]amino]-2-oxoethyl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-oxopentanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0120	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0130	uM
(4S)-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(1S)-1-carboxy-2-methylpropyl]amino]-5-oxopentanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0143	uM
(2S,3S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-methylpentanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0143	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0150	uM
(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0152	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0160	uM
(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]propanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0169	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0170	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-3-carboxy-2-[[(2S)-4-carboxy-2-[[(2S)-2-[[(2S)-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]butanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-methylpentanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0172	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-carboxypropanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0191	uM
(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0200	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0200	uM
(4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S,3R)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0208	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0220	uM
(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0227	uM
(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0228	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-oxobutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0260	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0260	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0260	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0280	uM
(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0294	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid	50714: MHC class I HLA-A*0201 binding affinity assayed by based inhibition of binding of a radiolabeled standard peptide (FLPSDYFPSV)	ic50	0.0331	uM

CTD chemical–gene interactions

81 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	6
sodium arsenite	decreases expression, increases expression	2
Vehicle Emissions	increases abundance, affects cotreatment, increases expression	2
Carbamazepine	affects response to substance	2
Cisplatin	affects response to substance, affects cotreatment, increases expression	2
Estradiol	affects cotreatment, decreases expression, increases expression	2
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression, affects expression	2
aristolochic acid I	increases expression	1
FR900359	affects phosphorylation	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
deoxynivalenol	decreases expression	1
quercitrin	affects expression	1
butyraldehyde	increases expression	1
beryllium sulfate	increases expression	1
aflatoxin G1	decreases expression	1
gossypol acetic acid	increases expression	1
ceric oxide	decreases expression	1
phenanthrene	decreases expression	1
nivalenol	decreases expression	1
chloropicrin	decreases expression	1
brinzolamide	affects expression	1
entinostat	increases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	increases expression	1
ICG 001	increases expression	1
bisphenol B	increases expression	1
abrine	increases expression	1
Indirubin E804	affects cotreatment, decreases expression	1
7-bromoindirubin-3’-oxime	affects cotreatment, decreases expression	1
bisphenol S	increases expression	1

ChEMBL screening assays

4 unique, capped per target: 4 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4235172	Binding	Binding affinity to human biotinylated HLA-A2 by surface plasmon resonance assay	Discovery of small molecule inhibitors of adenovirus by disrupting E3-19K/HLA-A2 interactions. — Bioorg Med Chem Lett

Cellosaurus cell lines

75 cell lines: 35 cancer cell line, 19 induced pluripotent stem cell, 15 transformed cell line, 5 spontaneously immortalized cell line, 1 hybrid cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_9U98	C1R-A2	Transformed cell line	Female
CVCL_A0WA	A549-A2-ESO	Cancer cell line	Male
CVCL_A1DV	624-mel/A31	Cancer cell line	Male
CVCL_A1DW	397-mel/A31	Cancer cell line	Sex unspecified
CVCL_A5AN	A904L-A26	Cancer cell line	Male
CVCL_B1C8	Abcam A-431 HLA-A KO	Cancer cell line	Female
CVCL_B7RM	K562/A*0201	Cancer cell line	Female
CVCL_B8HF	Abcam HCT 116 HLA-A KO	Cancer cell line	Male
CVCL_B8WT	Abcam MCF-7 HLA-A KO	Cancer cell line	Female
CVCL_B9JQ	Abcam A-549 HLA-A KO	Cancer cell line	Male

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery